Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSIP1 | O75475 | 5/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2041498 | 0.92 | PSIP1 (0.46) | PSIP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2045772 | 0.88 | PSIP1 (0.61) | PSIP1 | |
| SCHEMBL458548 | 0.84 | KDR (0.37) | PSIP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2041516 | 0.84 | PDE4A (0.36) | PSIP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2047877 | 0.82 | PSIP1 (0.50) | PSIP1 | |
| SCHEMBL2051121 | 0.82 | PSIP1 (0.48) | PSIP1 | |
| SCHEMBL2047259 | 0.81 | PSIP1 (0.54) | PSIP1 | |
| SCHEMBL2041961 | 0.80 | PSIP1 (0.57) | PSIP1 | |
| SCHEMBL459408 | 0.80 | PSIP1 (0.38) | PSIP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2040149 | 0.79 | PSIP1 (0.45) | PSIP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516008-B1 | NOVEL ANTIVIRAL COMPOUNDS | UNIV LEUVEN KATH (BE) | 2014-04-16 | — | — | EP | claimed |
| EP-2516008-B1 | NOVEL ANTIVIRAL COMPOUNDS | UNIV LEUVEN KATH (BE) | 2014-04-16 | — | — | EP | disclosed |
| US-20120316161-A1 | NOVEL ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-12-13 | — | — | US | disclosed |
| EP-2516008-A1 | NOVEL ANTIVIRAL COMPOUNDS | Katholieke Universiteit Leuven (BE) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011076765-A1 | NOVEL ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316161-A1 | NOVEL ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | PSIP1 1892/4885PDE4A 624/4885PDE4B 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.